Latest Earnings Results: Q2 '26
Estimated EPS
-$0.06
Reported EPS
-$0.12
Surprise
-111.76%
Estimated Rev
$26.49M
Reported Rev
$29.1M
Surprise
+9.87%
• Reported GAAP EPS of -$0.12 • Reported revenue of $29.11M up 8.72% YoY • Gyre Therapeutics, Inc. affirmed its full year 2026 revenue guidance of $100.5 million to $111.0 million, reflecting the company's outlook for its commercial-stage biopharmaceutical product portfolio and development initiatives.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.12 | -- | -- | N/A |
Q2 '26 | -$0.06 | -$0.12 | -111.76% | MISSED |
Q1 '26 | -$0.07 | -$0.10 | -36.36% | MISSED |
Q4 '25 | $0.06 | -$0.02 | -135.29% | MISSED |
Q3 '25 | $0.03 | $0.03 | 12.50% | BEAT |